Carter to lead Fusion Energy Division at Oak Ridge National Laboratory
As Frontier, the world’s first exascale supercomputer, was being assembled at the Oak Ridge Leadership Computing Facility in 2021, understanding its performance on mixed-precision calculations remained a difficult prospect.
Quantum computers process information using quantum bits, or qubits, based on fragile, short-lived quantum mechanical states. To make qubits robust and tailor them for applications, researchers from the Department of Energy’s Oak Ridge National Laboratory sought to create a new material system.
Speakers, scientific workshops, speed networking, a student poster showcase and more energized the Annual User Meeting of the Department of Energy’s Center for Nanophase Materials Sciences, or CNMS, Aug. 7-10, near Market Square in downtown Knoxville, Tennessee.
The Department of Energy’s Office of Science has selected three ORNL research teams to receive funding through DOE’s new Biopreparedness Research Virtual Environment initiative.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
Outside the high-performance computing, or HPC, community, exascale may seem more like fodder for science fiction than a powerful tool for scientific research. Yet, when seen through the lens of real-world applications, exascale computing goes from ethereal concept to tangible reality with exceptional benefits.
A new nanoscience study led by a researcher at ORNL takes a big-picture look at how scientists study materials at the smallest scales.
Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.
A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.
After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.